Bryan Yoon
Director de Operaciones en TERNS PHARMACEUTICALS, INC. .
Fortuna: 404 371 $ al 30/04/2024
Cargos activos de Bryan Yoon
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TERNS PHARMACEUTICALS, INC. | Director de Operaciones | 01/11/2020 | - |
Consejero General | 01/11/2020 | - | |
Secretario Corporativo | 01/01/2021 | - |
Historial de carrera de Bryan Yoon
Antiguos cargos conocidos de Bryan Yoon.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
LOGICBIO THERAPEUTICS, INC. | Director Administrativo | 01/11/2019 | 06/11/2020 |
Consejero General | 01/11/2019 | 06/11/2020 | |
Secretario Corporativo | 01/11/2019 | 06/11/2020 | |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Director/Miembro de la Junta | 08/01/2018 | 07/06/2019 |
NIGHTSTAR THERAPEUTICS PLC | Consejero General | 01/11/2017 | 01/06/2019 |
Secretario Corporativo | 01/02/2018 | 01/06/2019 | |
INTERCEPT PHARMACEUTICALS, INC. | Consejero General | 01/01/2013 | 01/11/2017 |
Secretario Corporativo | 01/01/2013 | 01/11/2017 |
Formación de Bryan Yoon.
Cornell University | Graduate Degree |
The University of Michigan Law School | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 6 |
Reino Unido | 3 |
Operativa
General Counsel | 4 |
Corporate Secretary | 4 |
Graduate Degree | 2 |
Sectorial
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
INTERCEPT PHARMACEUTICALS, INC. | Health Technology |
TERNS PHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Nightstar Therapeutics Ltd.
Nightstar Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Nightstar Therapeutics Ltd. is a clinical-stage gene therapy. It engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded by Robert MacLaren, Miguel Seabra and Matthew During in 2014 and is headquartered in London, the United Kingdom. | Health Technology |
NightstaRx Ltd.
NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Health Services |
LogicBio Therapeutics, Inc.
LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Bryan Yoon
- Experiencia